AKBA (Akebia Therapeutics Inc) שולי הרווח הגולמי

סמלים רשמיים של חברת Akebia Corp (AKBA)

Akebia Therapeutics (AKBA) maintains a stable staff of regulatory and go-to-market experts. The development of new agents is based on AI algorithms and automated synthesis. Company revenues rely on the supply of Vafseo to pharmacies and dialysis centers. Sales margins reflect cost dynamics, where the value 78.20 denotes the current production efficiency metric.

AKBA: שולי רווח גולמי Akebia Therapeutics, Inc. 04.07.2022 - 21.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Akebia Therapeutics (AKBA)

- מדדי הערכת שווי שוק של העסק:
- נתוני יתרות מזומנים ותזרימי מזומנים:
ניתוח מסכם של החברה:Akebia Therapeutics, Inc. - AKBA
מוצר המיוצר על ידי Akebia Corp

For Akebia Therapeutics (AKBA), the gross profit margin reflects the efficiency of monetizing patents for anemia drugs amid price regulations imposed by government programs. This indicator is calculated as the ratio of the difference between revenue and direct cost of goods sold to total sales, allowing investors to assess the business's fundamental ability to generate profit before accounting for operating expenses.